Seeking Alpha

Nick Zheng

View as an RSS Feed
View Nick Zheng's Comments BY TICKER:
Latest  |  Highest rated
  • Exact Sciences' Stool-DNA-Based Colorectal Cancer Screening Test Likely To Get Favorable Review On Its PMA [View article]
    If Cologaurd is too expensive, the non-invasive CT-scan will be endorsed, rather than another stool test. No long term survival hope for Cologuard, I feel.
    Mar 24 01:40 PM | Likes Like |Link to Comment
  • Exact Sciences' Stool-DNA-Based Colorectal Cancer Screening Test Likely To Get Favorable Review On Its PMA [View article]
    Agree that panel will vote positively, but do not think it is a strong buy.
    FIT/FOBT at $20/pop will stay as they are already endorsed by many insurers. Cologuard is more sensitive? yes. But it also has more "No Calls" and false positive. Marketing will be slow and tough.
    Mar 24 01:36 PM | Likes Like |Link to Comment
  • Behind The Short, Are Investors Of CytRx That Shallow?  [View instapost]
    make senses. All try to manipulate the stock price. I do not see much difference among all analysts, pumpers, dumpers, journalists, columnists. It is up to the investors to judge by themselves. For biotech stocks, only the drugs that matter. If the company misleads the investors by fraudulent data, then it is a fraud. All others are noises.
    Mar 14 04:27 PM | 4 Likes Like |Link to Comment
  • Behind The Scenes With Dream Team, CytRx And Galena [View article]
    Any difference between Liana M of Wedbush when she is pumping CHTP and LJPC and Tom M of Dream Team when he is pumping CYTR, GALE, ISCO? I could not find any. Are they brother/sister of M?
    Both work with management to pump the stocks. The idiots are duped.
    Mar 13 03:37 PM | 2 Likes Like |Link to Comment
  • DARA: Next Steps After Awarding Of Orphan Designation For KRN5500 [View article]
    The best intelligent comment I have ever read at seeking alpha. Those who do not understand the biochemistry/biomedicine believe what co and CPA/MBA say. KRN5500 is fundamentally wrong chemical for CCIPN.
    Feb 27 12:43 PM | Likes Like |Link to Comment
  • Still Betting On DARA Bio [View article]
    Could you tell me how a ODD helps approval? ODD just means there is a small population of pts that the drug targets. I do not see much value, and certainly not excited at all by the prospect of the drug, not to mention the measly sales numbers. Simply put, DARA is a failure. It is starving. To investors, it has been a trap.
    Feb 24 06:52 PM | Likes Like |Link to Comment
  • Chelsea: Trading Strategies For The Pending FDA Decision [View article]
    CHTP closed at 6.04 today (Friday, 2/21/14, Feb options expire today). All strategies presented in this article made money! Amazing.

    If you are right on FDA decision, you make a good money; if you are wrong, you make a little money. You just need to be right for a few times for each year using the right strategies, you should make a very good return. Is there a better investment strategy than this one: little or no risk but potentially huge reward?

    Many thanks to my partner Ted Arhontas for his brilliant ideas on option strategies.
    Feb 21 11:59 PM | Likes Like |Link to Comment
  • Chelsea: Trading Strategies For The Pending FDA Decision [View article]
    Usually on the PDUFA date (anytime Friday, 2/14/14), but news could come earlier or later.
    Feb 12 12:00 AM | Likes Like |Link to Comment
  • Chelsea: Trading Strategies For The Pending FDA Decision [View article]
    Dan, it is interesting to note that you believe delay is a quite bearish signal. If so, delay could be a more volatile event than I thought. The good thing will be that we will have another chance to play the binary event.
    Feb 11 07:32 PM | Likes Like |Link to Comment
  • Chelsea: Trading Strategies For The Pending FDA Decision [View article]
    You are welcome. This is the main purpose of our article to present safer strategies for binary events.
    Feb 11 06:00 PM | Likes Like |Link to Comment
  • Chelsea: Trading Strategies For The Pending FDA Decision [View article]
    I have held no call options. The back ratio put option strategy is safe on approval assuming the stock price will be higher than 4.5 when options expire on Feb 21.
    Feb 11 05:57 PM | Likes Like |Link to Comment
  • Chelsea: Trading Strategies For The Pending FDA Decision [View article]
    Thank you, Nick. Make money while we have fun!
    Feb 11 05:47 PM | Likes Like |Link to Comment
  • Chelsea: Trading Strategies For The Pending FDA Decision [View article]
    The FDA reviewer did not vote. Read: "The second reviewer had an overall negative bias on the briefing documents, but in the end (the panel of advisors) voted for approval."
    Feb 11 05:36 PM | Likes Like |Link to Comment
  • Chelsea: Trading Strategies For The Pending FDA Decision [View article]
    For the most cases, delay is viewed as negative. But for this particular case, many are expecting a delay but a final approval later because FDA may need more time to discuss the labeling. If FDA had already made a decision to reject it, the agency could simply fax a letter to the company, which could be done quicker than approval. That being said, you could still be right. FDA could surprise anyone.
    Feb 11 12:31 PM | Likes Like |Link to Comment
  • Chelsea: Trading Strategies For The Pending FDA Decision [View article]
    yeah, you are absolutely right. Some professors are stupid and biased. Sure, I could be more stupid and biased, right? :)
    Feb 11 12:26 PM | 1 Like Like |Link to Comment
COMMENTS STATS
135 Comments
119 Likes